BioPharma

BioPharma-Synergy (23rd -25th February 2021)

The event is designed for the BD&Licensing pharma professionals focusing on BioSimilars, BioBetter & BioInnovative products. With the audience coming from Europe, LATAM, APAC, MENA & North America – BioPharma-Synergy invites dynamic pharma companies for three days of business partnering meetings and content-driven programme.

Speaker faculty includes:

  • Jean-Baptiste Duval, Head of International Operations, Shanghai Henlius Biotech
  • Philippe Gautron, Senior Director, Global Business Development own brands, DKSH
  • Eduardo Cioppi, Regional Director – Latin America, mAbxience
  • Stephani Saverio, Senior Director, Business Development, Knight Therapeutics
  • Xiaoli Hu, Head of Business Development, Xbrane Biopharma AB
  • Pavan Handa, Executive Vice President and Chief Business Officer, Kashiv Pharm
  • Thiago Mares Guia, Scientific & Business Executive Director, Bionovis
  • Carlos Berrade, Licensing & Business Development Director, Kern Pharma
  • Marco Cerato, Senior Vice President, Global Corporate and Business Development, Mundipharma
  • Anil Okay, General Manager at Adalvo, Chief Commercial Officer, Alvotech
  • Gopal Rao, Global Business Development, Biotech Division Lupin
  • Radhika Bhalla, Head of Emerging Asia Alliance Markets, Viatris
  • Bert Thomas, SVP Business Development, Bio-Thera Solutions
  • Wen Ries-Shi, VP Europe General Manager, Techdow Pharma Shenzhen, Hepalink Pharmaceutical Group 
  • Debraj Dasgupta, VP, Global Head of Strategic Portfolio and Markets, Biocon Biologics

Discussions and presentations

The 2021 content-driven programme will focus on successful commercial strategies, pricing consideration, facilitating partnering across Geos between producers and buyers. Among the topics:

Global Biosimilars/Biobetter outlook; key players and their market access strategies

Regulatory approvals, tenders and pricing trends in Europe

Opportunities and trends in biosimilars by region: APAC, MENA, CIS, LATAM

Strategic considerations for biosimilar commercialisation – manufacturers’ point of view

In-licensing strategies in Europe and beyond

See what speakers say about the event

Watch the online discussion that took place in July 2020: “Global Biosimilars Landscape and Opportunities”